Overview
I am a clinical investigator in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine. I serve as Director of the Leukemia Program and Director of Phase I Development in Hematologic Malignancies. I am also the Chair of the SWOG Leukemia Committee. I am interested in the clinical development of novel therapies for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms (such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia and myelofibrosis), and acute lymphoblastic leukemia. Specifically, I have been the Principal Investigator for small molecular inhibitors, antibody-drug conjugates and cytotoxic chemotherapy.
Office Hours
Office hours:
Monday, 8 a.m. to 12 p.m.
Tuesday, 8 a.m. to 5 p.m.
Wednesday, 8 a.m. to 12 p.m.
Friday, 1 p.m. to 5 p.m.
Current Appointments & Affiliations
Professor of Medicine
·
2023 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2018 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203.
Journal Article Leukemia · March 2025 Full text Link to item CiteFrontline Therapy of AML in the Fit and Younger Population-Incorporating Molecularly Targeted Agents.
Journal Article Am J Hematol · March 2025 Backbone therapy for acute myeloid leukemia for younger adults has for 50 years been based on a combination of cytarabine and anthracycline. Over the past 10 years the addition of several targeted agents has been found to improve the outcomes of subsets of ... Full text Link to item CiteRecent Grants
Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia
Clinical TrialPrincipal Investigator · Awarded by Kura Oncology · 2024 - 2029CL04-ORY-1001
Clinical TrialPrincipal Investigator · Awarded by Oryzon Genomics SA · 2023 - 2028Novartis Phase II MBG453 in combination with Venetoclax and Azacitidine in AML
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2020 - 2028View All Grants
Education, Training & Certifications
Medical Licensure Commission of Alabama ·
2012
Lic.
Stanford University, School of Medicine ·
1988
M.D.
Stanford University ·
1988
Ph.D.